Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger

Pituitary Downregulation Clinical Trial

Official title:

Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03044756
• Other study ID #: Omit
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: February 1, 2017
• Last updated: February 6, 2017
• Start date: January 1, 2017
• Est. completion date: December 30, 2017

Study information

• Verified date: February 2017
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Omitting the GnRH antagonist on the day of the trigger can be cost effective and more convenient to the women. We will study the impact of omitting the antagonist dose in a prospective randomized trial

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 30, 2017
• Est. primary completion date: August 30, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• All antagonist cycle ivf who agree to participate

Exclusion Criteria:

• expected poor responders.

Related Conditions & MeSH terms

• Pituitary Diseases
• Pituitary Downregulation

Intervention

Drug:
• Omit Citrotide 0.25 dose on the day of triggering of ovulation
Omit Citrotide 0.25 dose on the day of triggering of ovulation

Locations

Country	Name	City	State
Egypt	Osama Abdalmageed	Assiut	Non-US/Non-Canadian
Egypt	Osama Abdalmageed	Assiut	Non-US/Non-Canadian

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Chang HJ, Lee JR, Jee BC, Suh CS, Lee WD, Kim SH. Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study. Clin Exp Reprod Med. 2013 Jun;40(2):83-9. doi: 10.5653/cerm.2013.40.2.83. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of retrieved oocytes	total number and maturation of the retrieved oocytes	One Month